New concepts in mood stabilization

Evidence for the effectiveness of valproate and lamotrigine

Charles L. Bowden

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Recognition of limited overall benefits from lithium in bipolar disorder, with even greater disadvantages in more severe forms of the disease, has spurred interest in alternative therapies. A long history of development of evidence for the utility of valproate has culminated in well-designed, placebo-controlled studies that establish the efficacy of the divalproex form of valproate in acute mania. Generally positive, but as yet not conclusive, studies indicate continued benefits in prophylactic treatment of bipolar disorder. The spectrum of efficacy of valproate is somewhat broader than that of lithium, extending to patients with certain more severe forms of the illness; e.g., mixed manics. Pretreatment plasma GABA activity was positively correlated with magnitude of improvement in manic symptomatology with divalproex. The evidence of comparable clinical benefits for lithium and valproate has stimulated studies that indicate overlapping effects on specific G protein-linked signal transduction for lithium and valproate, but not for carbamazepine. The possibility that additional antiepileptic drugs might have efficacy in bipolar disorder has encouraged early clinical studies with several newer antiepileptic drugs. Preliminary evidence for the efficacy of one of these, lamotrigine, has been presented.

Original languageEnglish (US)
Pages (from-to)194-199
Number of pages6
JournalNeuropsychopharmacology
Volume19
Issue number3
DOIs
StatePublished - Sep 1998

Fingerprint

Valproic Acid
Bipolar Disorder
Lithium
Anticonvulsants
Carbamazepine
Complementary Therapies
lamotrigine
GTP-Binding Proteins
gamma-Aminobutyric Acid
Signal Transduction
Placebos

Keywords

  • Bipolar disorder
  • Lamotrigine
  • Manic-depressive
  • Valproate

ASJC Scopus subject areas

  • Pharmacology

Cite this

New concepts in mood stabilization : Evidence for the effectiveness of valproate and lamotrigine. / Bowden, Charles L.

In: Neuropsychopharmacology, Vol. 19, No. 3, 09.1998, p. 194-199.

Research output: Contribution to journalArticle

@article{67e33261a34b4bbfb230962051e5f69d,
title = "New concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigine",
abstract = "Recognition of limited overall benefits from lithium in bipolar disorder, with even greater disadvantages in more severe forms of the disease, has spurred interest in alternative therapies. A long history of development of evidence for the utility of valproate has culminated in well-designed, placebo-controlled studies that establish the efficacy of the divalproex form of valproate in acute mania. Generally positive, but as yet not conclusive, studies indicate continued benefits in prophylactic treatment of bipolar disorder. The spectrum of efficacy of valproate is somewhat broader than that of lithium, extending to patients with certain more severe forms of the illness; e.g., mixed manics. Pretreatment plasma GABA activity was positively correlated with magnitude of improvement in manic symptomatology with divalproex. The evidence of comparable clinical benefits for lithium and valproate has stimulated studies that indicate overlapping effects on specific G protein-linked signal transduction for lithium and valproate, but not for carbamazepine. The possibility that additional antiepileptic drugs might have efficacy in bipolar disorder has encouraged early clinical studies with several newer antiepileptic drugs. Preliminary evidence for the efficacy of one of these, lamotrigine, has been presented.",
keywords = "Bipolar disorder, Lamotrigine, Manic-depressive, Valproate",
author = "Bowden, {Charles L.}",
year = "1998",
month = "9",
doi = "10.1016/S0893-133X(98)00025-6",
language = "English (US)",
volume = "19",
pages = "194--199",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - New concepts in mood stabilization

T2 - Evidence for the effectiveness of valproate and lamotrigine

AU - Bowden, Charles L.

PY - 1998/9

Y1 - 1998/9

N2 - Recognition of limited overall benefits from lithium in bipolar disorder, with even greater disadvantages in more severe forms of the disease, has spurred interest in alternative therapies. A long history of development of evidence for the utility of valproate has culminated in well-designed, placebo-controlled studies that establish the efficacy of the divalproex form of valproate in acute mania. Generally positive, but as yet not conclusive, studies indicate continued benefits in prophylactic treatment of bipolar disorder. The spectrum of efficacy of valproate is somewhat broader than that of lithium, extending to patients with certain more severe forms of the illness; e.g., mixed manics. Pretreatment plasma GABA activity was positively correlated with magnitude of improvement in manic symptomatology with divalproex. The evidence of comparable clinical benefits for lithium and valproate has stimulated studies that indicate overlapping effects on specific G protein-linked signal transduction for lithium and valproate, but not for carbamazepine. The possibility that additional antiepileptic drugs might have efficacy in bipolar disorder has encouraged early clinical studies with several newer antiepileptic drugs. Preliminary evidence for the efficacy of one of these, lamotrigine, has been presented.

AB - Recognition of limited overall benefits from lithium in bipolar disorder, with even greater disadvantages in more severe forms of the disease, has spurred interest in alternative therapies. A long history of development of evidence for the utility of valproate has culminated in well-designed, placebo-controlled studies that establish the efficacy of the divalproex form of valproate in acute mania. Generally positive, but as yet not conclusive, studies indicate continued benefits in prophylactic treatment of bipolar disorder. The spectrum of efficacy of valproate is somewhat broader than that of lithium, extending to patients with certain more severe forms of the illness; e.g., mixed manics. Pretreatment plasma GABA activity was positively correlated with magnitude of improvement in manic symptomatology with divalproex. The evidence of comparable clinical benefits for lithium and valproate has stimulated studies that indicate overlapping effects on specific G protein-linked signal transduction for lithium and valproate, but not for carbamazepine. The possibility that additional antiepileptic drugs might have efficacy in bipolar disorder has encouraged early clinical studies with several newer antiepileptic drugs. Preliminary evidence for the efficacy of one of these, lamotrigine, has been presented.

KW - Bipolar disorder

KW - Lamotrigine

KW - Manic-depressive

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=0032171603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032171603&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(98)00025-6

DO - 10.1016/S0893-133X(98)00025-6

M3 - Article

VL - 19

SP - 194

EP - 199

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -